15 August 2023
A success story that reaches back three decades
2023 marks the 30th anniversary of producing Tramadol in Mitlödi, Switzerland! Our team at this state-of-the-art facility has given patients around the globe a reliable supply of this vital pain treatment for three decades.
The story of Tramadol starts in 1977 when Grünenthal scientists successfully developed the first-ever pain therapy from our research labs. This breakthrough transformed our company into the pain specialist we are today. We shifted production to Mitlödi in 1993. Today, the site supplies this Active Pharmaceutical Ingredient (API) to pain patients around the globe – and is the largest Tramadol production plant in the world. Our team in Mitlödi produces about one-third of the global demand for Tramadol.
“Together, our colleagues in Mitlödi have ensured a safe, efficient and reliable supply of Tramadol-containing products for patients worldwide”, says Victor Barbosa, Head of Global Operations at Grünenthal. “It is a success story that now reaches back three decades into the past – and will reach into the future for many more decades to come.”
“Together, our colleagues in Mitlödi have ensured a safe, efficient and reliable supply of Tramadol-containing products for patients worldwide.”
Victor Barbosa,
Head of Global Operations, Grünenthal
Our 30th anniversary of producing this prescription pain medicine in Switzerland is the latest milestone for this incredibly successful factory. The local team’s sharp focus on continuous improvement makes its competitive power possible. The facility operates 24 hours a day and seven days a week and is powered by 100 per cent renewable electricity from a local hydropower plant. And the team of around 65 colleagues voted Mitlödi as a Great Place to Work in 2022.
Grünenthal’s deep commitment to our location in Switzerland is reflected by long-term strategic decision-making about expanding the portfolio produced at this site.
Further Information on Grünenthal can be found in our Grünenthal Report 2022/2023 Digital Edition or in our Grünenthal Reports PDF
M-N/A-DE-01-23-0007
